Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287670 · ClinicalTrials.gov registry record · Phase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2 study, sponsored by Mediar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT07287670: Recruiting Phase 2 study, sponsored by Mediar Therapeutics.
NCT07287670 is a Phase 2 study that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287670, a Phase 2 study, is actively recruiting participants, sponsored by Mediar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Primary Outcome
Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas. Unit of measure: Score (range 0-51)
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07287670 shows while recruiting
NCT07287670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07287670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07287670 about?
NCT07287670 is a clinical study titled "EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)". A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
What is the current status of trial NCT07287670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2026-04-16. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07287670?
The interventions under investigation include: Placebo (OTHER), MTX-474 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07287670?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07287670's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI